Bharti Airtel shares increased on Wednesday following the telecom giant's announcement of strong earnings for the March quarter, led by healthy operating numbers and an announcement of a final dividend.
The stock rose up to 2.7% to ₹ 1,869, before closing around ₹1,862, ranking it as one of the top NIFTY 50 index gainers. As of 12:30 PM, the stock is trading at ₹1,828.60 with a marginal increase of 0.43%
Bharti Airtel posted net profit of ₹11,022 crore for Q4 FY25, a fivefold rise from ₹ 2,071.6 crore in the comparable quarter last year. Even stripping out exceptional items, profit remained at ₹5,223 crore, marking 77% year-on-year growth.
Revenue from operations went up 27% YoY to ₹47,876 crore, on the back of robust growth across mobility, data, and digital services.
Key performance indicators showed continued momentum. Mobile Average Revenue Per User (ARPU) increased to ₹245, a 17% YoY increase. Mobile data usage was up 21.2%, and the number of smartphone data customers increased 24 million during the year. These customers now make up 77% of the overall mobile customer base, highlighting the company's continued digital transformation.
The company also declared a final dividend of ₹16 per equity share in FY25, instilling confidence in shareholder payouts and cash flow returns.
While the stock is gaining today, it has declined 4% over the past five sessions. However, it has delivered a 1.4% gain over one month, 18% over six months, and a strong 42% return over the past year, significantly outperforming the Nifty 50’s 10.6% annual gain.
Being a heavyweight on the benchmark index and a significant operator in the telecom industry, Bharti Airtel's performance is keenly followed for larger cues on the health of the industry, sentiment in the market, and consumption patterns.
The recent earnings reiterate the company's emphasis on high-value subscribers and data monetisation as prime drivers of growth.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.